Medindia

X

Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan

Wednesday, October 21, 2009 General News J E 4
Advertisement


LONDON, Oct. 20 The global recession will have limited effect on the lifesciences industry. However, internal factors and external issues such as weak product pipelines, generic competition and declining market shares are pressurising lifesciences companies to cut down their IT budgets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.healthcareIT.frost.com), Competitive Profiling of Market Participants in Lifesciences-IT, finds that the market was worth $26.5 billion in 2008 and is estimated to reach $41.6 billion in 2015.

"SaaS technology will be adopted by pharmaceutical companies as it is cost effective and offers enhanced flexibility options," notes Frost & Sullivan Industry Analyst E. Sujith. "The lifesciences industry is focusing on outsourcing its operations to reduce costs, creating a new market for vendors of IT solutions."

Pharmaceutical companies are moving to outsource operations to countries including India, China and Singapore as a cost-cutting measure. Despite the pharmaceutical industry increasingly rationalising and rightsizing its outsourcing, this still presents a substantial market.

Pharmaceutical companies are reducing their IT budgets. They are also rationalising new purchases due to uncertainties in the industry.

"Pharmaceutical and biotechnology companies are confronting issues such as a flood of generics, intensified competition, shrinking drug pipelines and lowered cash flows," cautions Sujith. "This is discouraging them from investing in IT-related expenses."

Accordingly, service providers should revise their pricing models. These could shift from effort-based pricing methods to potentially more successful outcome-based partnership contracts.

"The performance-based pricing model has been widely accepted in the marketplace during the recession and vendors would benefit by following this model," advises Sujith. "The IT cost efficiency compared to productivity of the business in exploring the cost is now a corporate wide strategy for maximising business productivity from the costs."

Competitive Profiling of Market Participants in Lifesciences-IT is part of the Healthcare & Life Sciences IT Growth Partnership Services programme, which also includes research in the following markets: European Medical Equipment Services Market, European market for Medical Display Monitors, Archiving Requirements for Image Management and European PACS Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Competitive Profiling of Market Participants in Lifesciences-IT

M3E1

http://www.frost.com

Contact: Katja Feick Corporate Communications - Europe P: +49 (0) 69 7703343 E: katja.feick@frost.com

SOURCE Frost & Sullivan
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ICFH Monster Fundraiser
S
Simcere Pharmaceutical Group Announces Collaborati...